Biogen and Eisai Amend their Collaboration Agreement on Aduhelm for Alzheimer’s Disease
Shots:
- As per amended collaboration, Eisai will receive tiered royalties starting at a rate of 2%, rising to 8% if annual sales exceed $1B and will no longer share profits and losses with Biogen on the Aduhelm (aducanumab), effective as of Jan 01, 2023
- Following the tiered royalty model, Eisai will not participate in Aduhelm’s economics beyond royalties. Biogen will solely responsible for decision making and commercialization rights of Aduhelm globally
- Both the companies continue the collaboration on lecanemab without any change in the agreement. The supply agreement related to lecanemab has been extended from 5 to 10 years
Ref: Biogen | Image:Biogen
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
